Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cranberry AIWA is an oral dietary supplement developed by T&D Pharma GmbH, designed to support urinary tract health. The primary active components are proanthocyanidins (PACs) derived from cranberry extract. These compounds function by inhibiting the adhesion of P-fimbriated *Escherichia coli* bacteria to the uroepithelial cells of the bladder wall. By preventing bacterial attachment, the supplement interferes with the initial stage of infection, thereby reducing the incidence of recurrent urinary tract infections (UTIs). It is marketed as a nutritional supplement rather than a prescription pharmaceutical and is part of the AIWA product line in Germany.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cranberry AIWA.